Conclusions and Relevance
CIPN, breast cancer
CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, SIDE EFFECT, BREAST CANCER
Baseline BMI may be a risk factor for CIPN and suboptimal chemotherapy delivery due to CIPN may negatively impact disease-free survival in patients with breast cancer. Further study is warranted to identify mitigating lifestyle factors to reduce incidences of CIPN during breast cancer treatment.Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy. This study aimed to identify patient characteristics associated with CIPN severity during weekly paclitaxel chemotherapy in people with early-stage breast cancer.